Tetravalent dengue vaccine: Phase III started

sanofi-aventis' Sanofi Pasteur S.A. vaccines division began an Australian Phase III trial to evaluate subcutaneous tetravalent dengue vaccine in 715 healthy volunteers. The pharma said the trial is t...